Zobrazeno 1 - 10
of 30
pro vyhledávání: ''
Autor:
Karen Kelly, Everett E. Vokes, Jonathan W. Goldman, Rebecca S. Heist, Apurvasena Parikh, D. Ross Camidge, J. Wu, Minal A. Barve, Bruce A. Bach, Eric Angevin, Zhaowen Sun, David S. Hong, Philip Komarnitsky, John H. Strickler, Todd M. Bauer, Daniel Morgensztern, Monica Motwani
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(21)
Purpose: Telisotuzumab vedotin (Teliso-V) is an anti–c-Met–directed antibody–drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules
Autor:
Chia-Chi Lin, Timothy A. Yap, Anna M. Szpurka, Maria de Miguel, Xiaojian Xu, Shelly Schmidt, Kay Hoong Chow, Antoine Italiano, Yumin Zhao, Yung Jue Bang, Michelle Carlsen, Wu Chou Su, Hyun Cheol Chung, Amita Patnaik, Burkhard Vangerow, Johanna C. Bendell, Danni Yu, Leena Gandhi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(5)
Purpose: This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib
Autor:
Bonnie S. Glisson, Yanan Zheng, Bhumsuk Keam, Steven Eck, Sandip Pravin Patel, Sanjay Goel, Matthew Gribbin, James Ohr, Naiyer A. Rizvi, Danielle M. Townsley, Katie Streicher, Reva Schneider, John D. Powderly, Jennifer Burton, Rom Leidner, Robert L. Ferris
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(20)
Purpose: Immune checkpoint blockade has demonstrated clinical benefits across multiple solid tumor types; however, resistance and relapse often occur. New immunomodulatory targets, which are highly expressed in activated immune cells, are needed. MED
Autor:
Jay Feingold, Joseph Boni, Mehdi Hamadani, Karin Havenith, David Ungar, Leonard T. Heffner, Paolo Caimi, Brad S. Kahl, Kirit M. Ardeshna, Erin Reid, John Radford, Owen A. O'Connor, Carmelo Carlo-Stella, Shui He, Melhem Solh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(23)
Purpose: ADCT-402 (loncastuximab tesirine) is an antibody–drug conjugate comprising a CD19-targeting antibody and pyrrolobenzodiazepine dimers. A first-in-human study evaluated the safety and preliminary clinical activity of loncastuximab tesirine
Autor:
Kyriakos P. Papadopoulos, Larry Gluck, Erik Rasmussen, Joe Stephenson, Gataree Ngarmchamnanrith, Lainie P. Martin, Anthony W. Tolcher, Dirk Nagorsen, John S. Hill, Benny Amore, Anthony J. Olszanski
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(19)
Purpose: Binding of colony-stimulating factor 1 (CSF1) ligand to the CSF1 receptor (CSF1R) regulates survival of tumor-associated macrophages, which generally promote an immunosuppressive tumor microenvironment. AMG 820 is an investigational, fully h
Autor:
Tuan S. Nguyen, Paul G. Richardson, Ilaria Conti, James E. Wooldridge, Edward A. Faber, Christopher Kaiser, Damien M. Cronier, Raymond J. Hohl, Susan P. Carpenter, Adam D. Cohen, Gary J. Schiller, Kenneth C. Anderson, Noopur Raje, Andres Forero
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(23)
Purpose: Tabalumab, a human mAb that neutralizes B-cell–activating factor (BAFF), demonstrated antitumor activity in xenograft models of multiple myeloma. Here we report on a phase I study of relapsed/refractory multiple myeloma patients in which t
Autor:
Jordi Rodon, Adedigbo Fasanmade, Thea Kalebic, Cristina Cruz, Wells A. Messersmith, Jung Ah Jung, Tim Wyant, Jason E. Faris, Khaldoun Almhanna, David P. Ryan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(20)
Purpose: To assess the safety, tolerability, and preliminary antitumor activity of the investigational anti–guanylyl cyclase C (GCC) antibody–drug conjugate TAK-264 (formerly MLN0264) in adult patients with advanced gastrointestinal malignancies.
Autor:
Cristina Noberasco, Roger B. Cohen, Marina Carpentieri, Francesco Bertolini, Filippo de Braud, Laura W. Goff, Hossein Borghaei, Jordan Berlin, Corrado Gallo Stampino, Antonello Abbattista, Erjan Wang, Andrej Lyshchik
Publikováno v:
Clin Cancer Res
Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II dose (RP2D) of the first-in-class anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962, and assess safety and antitumor activity
Autor:
Catherine Littman, Andrea Pirzkall, David S. Shames, Andrés Cervantes, George R. Blumenschein, Sandra Sanabria Bohorquez, Amy V. Kapp, Dejan Juric, Rodrigo Dienstmann, Wells A. Messersmith, Lukas C. Amler, X. Wang, José Baselga, Antonio Jimeno, Antonio Calles, Cecilia Leddy, Elicia Penuel, Manuel Hidalgo, Desamparados Roda, Josep Tabernero
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(11)
Purpose: The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer signaling. This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of MEHD7945A.
Autor:
Jean Fishel, Mrinal M. Gounder, Susan C. Weil, Luigi Grasso, Susan Lawrence, Richard D. Carvajal, Christina M. Coughlin, Nilofer S. Azad, Wolfgang Ebel, Luis A. Diaz, Jason Wustner, Daniel J. O'Shannessy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 21(6)
Purpose: Endosialin (TEM-1, CD248) is a protein expressed on the surface of activated mesenchymal cells, including certain subsets of tumors. Preclinical models suppressing endosialin function have shown antitumor activity. A humanized monoclonal ant